Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Keros Therapeutics to post earnings of ($1.13) per share and revenue of $3.83 million for the quarter.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $3.63. The firm had revenue of $211.25 million during the quarter, compared to analysts’ expectations of $84.62 million. Keros Therapeutics had a net margin of 1.96% and a return on equity of 0.75%. During the same period in the previous year, the company earned ($1.21) earnings per share. On average, analysts expect Keros Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Keros Therapeutics Trading Down 0.2%

Shares of NASDAQ KROS opened at $14.48 on Wednesday. The firm has a 50 day moving average of $14.05 and a 200 day moving average of $12.63. The firm has a market capitalization of $588.18 million, a price-to-earnings ratio of -80.44, a price-to-earnings-growth ratio of 2.62 and a beta of 1.26. Keros Therapeutics has a 12-month low of $9.12 and a 12-month high of $72.37.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently modified their holdings of KROS. Goldman Sachs Group Inc. raised its position in shares of Keros Therapeutics by 38.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Keros Therapeutics by 15.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock worth $227,000 after buying an additional 2,982 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new position in Keros Therapeutics during the 1st quarter worth approximately $226,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on KROS shares. HC Wainwright lowered their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Wedbush reissued a “neutral” rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Friday, May 30th. Truist Financial reduced their target price on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. Bank of America downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $32.00 to $18.00 in a research note on Tuesday, June 10th. Finally, Scotiabank cut their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a “sector outperform” rating on the stock in a report on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.